镭223联合立体定向消融放疗治疗激素初治寡转移前列腺癌的2期试验
这项前瞻性2期试验纳入20例骨-only寡转移激素敏感性前列腺癌患者,接受6周期镭223联合SABR(30 Gy/5次)。15个月和24个月无ADT生存率分别为50.0%和40.0%(P < .001),55%患者PSA下降超过50%,2例2年时PSA不可测。结论认为该方案较历史对照显著延迟ADT启动,耐受性好且维持生活质量。
要点
- 15个月和24个月无ADT生存率分别为50.0%和40.0%(P < .001)。
- 11例(55%)PSA下降超过50%,5例(25%)超过90%。
- 2例发生3级骨骼相关事件,镭223和SABR相关2级以上事件分别为4例和2例。
核心结论
- 在moHSPC患者中,初始使用镭223联合SABR较历史对照显著延迟ADT启动。
- 该治疗耐受性良好,维持生活质量,并可使部分患者2年时PSA不可测。
研究设计与样本
- 前瞻性2期试验纳入20例骨-only moHSPC且≤5处骨转移的男性患者,此前已接受前列腺和盆腔淋巴结根治性治疗。
- 入组标准为睾酮≥100 ng/dL且常规影像证实转移;排除初始治疗后LHRH治疗或骨转移诊断时N1病变。
- 治疗包括6周期镭223和SABR(30 Gy分5次),主要终点为15个月时≥20%患者免于ADT。
主要发现
- 镭223周期中位数为6。
- 15个月和24个月无ADT生存率分别为50.0%和40.0%(P < .001)。
- 11例(55%)PSA下降超过50%,5例(25%)超过90%,2例2年时PSA不可测(<0.01)。
- 患者报告结局生活质量各领域均无显著变化。
- 2例发生3级骨骼相关事件;归因于镭223和SABR的2级以上事件分别为4例和2例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We hypothesized that treatment with Radium223 (Ra223) and Stereotactic ablative radiotherapy (SABR) in patients with bone-only metachronous oligometastastic hormone-sensitive prostate cancer (moHSPC) could safely delay the start of androgen deprivation therapy (ADT) and maintain quality of life (QoL). METHODS AND MATERIALS: This prospective trial included 20 men with moHSPC and ≤5 bone-only metastases who previously had definitive treatment to the prostate and pelvic lymph nodes. Eligibility criteria were testosterone ≥ 100 ng/dL and metastases validated by conventional imaging. Exclusion criteria were postinitial treatment (LHRH) therapy or N1 disease at bone metastasis diagnosis. Treatment included 6 cycles of Ra223 and SABR (30 Gy in 5 fractions). Bone scans and Prostate Specific Antigen (PSA) levels were monitored regularly. The primary endpoint was freedom from ADT use at 15 months in ≥20% of patients. Patients were followed for 2 years, with clinically significant patient-reported outcome changes defined as >1/2 standard deviation from baseline. Statistical analyses used Wilcoxon rank sum, Pearson's χ2 tests, and univariate Cox regression, with significance set at P < .05 RESULTS: The median number of Ra223 cycles was 6. Freedom from ADT at 15 and 24 months was 50.0% and 40.0%, respectively (P < .001). Eleven (55%) and 5 (25%) patients had PSA declines exceeding 50% and 90%, respectively, with 2 patients achieving undetectable PSA levels (<0.01) at 2 years. No significant changes were observed in any patient-reported outcome QoL domains. Two patients had grade 3 skeletal-related events, and grade 2+ events attributed to Ra223 and SABR were observed in 4 and 2 patients, respectively. CONCLUSIONS: In this phase 2 trial, the initial use of Ra223 and SABR for moHSPC significantly delayed ADT use compared with historical controls. The therapy is well tolerated, preserves QoL, and can lead to undetectable PSA levels at 2 years.
引用
- Tward J, Lloyd S, Johnson S, et al. A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. Int J Radiat Oncol Biol Phys. 2025. PMID: 39922320. doi:10.1016/j.ijrobp.2025.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。